Ovarian Cancer Trial, Recruiting NCT05053230 Sponsor: Memorial Sloan Kettering Cancer Center Condition: Ovarian Cancer
Back to Ovarian Cancer

Ovarian Cancer Trial, Recruiting

NCT05053230
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years of age or older
  • You are well enough to carry out some normal daily activities (your doctor can confirm this using a standard health scoring tool)
  • You are expected to live for more than six months
  • You are able to speak English
  • For the Head & Neck, Thoracic, Gynecologic, Melanoma, and Breast group: You have been diagnosed with one of these cancer types AND are currently receiving cancer treatment or radiation therapy, or finished radiation therapy or major surgery within the last 4 weeks, AND your fatigue has been at least a 4 out of 10 in the past 7 days
  • For the First Remission Gynecologic Cancer group: You have been diagnosed with, or are suspected to have, a gynecologic cancer and have finished your main first course of treatment (ongoing hormone or targeted therapy is still allowed)
  • For the Advanced Cancer group: You have been diagnosed with a later-stage or advanced cancer (such as Stage III or IV lung, breast, ovarian, or other cancers listed — confirm specific cancer types with the trial site) AND are currently receiving treatment, radiation, or being monitored
  • For the Cancer Survivor group: You have finished active cancer treatment such as surgery, radiation, or chemotherapy (ongoing hormone or targeted therapy is still allowed), AND your fatigue has been at least a 4 out of 10 in the past 7 days

Who may not be able to join:

  • You have a cognitive or mental condition that would make it difficult for you to complete study questionnaires or assessments on your own
  • You are not willing to be randomly assigned to a treatment group in the study
  • You are already taking part in another clinical trial that is specifically testing complementary or integrative medicine approaches and measuring symptoms as the main goal (participating in other types of trials is still allowed)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 30 June 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
20 September 2021
Est. completion
20 September 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Average Fatigue Severity from the Brief Fatigue Inventory (BFI)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov